Literature DB >> 32580038

Inhibitory effect of melatonin on hypoxia-induced vasculogenic mimicry via suppressing epithelial-mesenchymal transition (EMT) in breast cancer stem cells.

Nazila Fathi Maroufi1, Maryam Amiri2, Babak Faraji Dizaji3, Vahid Vahedian4, Maryam Akbarzadeh5, Neda Roshanravan6, Sanya Haiaty7, Mohammad Nouri8, Mohammad-Reza Rashidi9.   

Abstract

Vasculogenic mimicry (VM) play an important role in breast cancer metastasis and anti- angiogenic drugs resistance. Hypoxia, the epithelial-mesenchymal transition (EMT), and cancer stem cells (CSCs) are known as essential factors for VM formation. Also, melatonin is an amino acid-derived hormone with many anti-tumor effects. Despite the antitumor effects of melatonin, its effect on VM formation in breast cancer has not been considered yet, so we investigated the effect of melatonin on VM formation through EMT process under hypoxia conditions in breast CSCs. The CSCs percentage and VM formation were determined in MCF-7 and MDA-MB-231, respectively. Also, analysis of HIF-1α expression under hypoxia in MDA-MB-231 and MCF-7 cell lines was performed using Western blot. The effect of melatonin on the VM formation, invasion, and migration was also investigated. Moreover, the effect of melatonin on the expression EMT markers was evaluated. CD44+ CD24-phenotype as CSCs marker in MDA-MB-231 cell line, was 80.8%, while it was 11.1% in MCF-7 cell line. HIF-1α expression was up-regulated in the VM-positive breast cancer cell line MDA-MB-231, and consequently, affected the expression of the EMT markers E-cadherin, vimentin, snail, and MMP9. Melatonin had significant effect on EMT and formations of VM in breast CSCs. Melatonin could prevent the formation of VM by affecting the important molecules involved in the formation of VM structures and the EMT. Moreover, our data clearly showed that, melatonin represents molecule with significant anti-cancer activities that may potentially optimize the management of breast cancer through the overcoming drug resistance in anti-angiogenic drugs.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Breast cancer; Cancer stem cell; Hypoxia; Melatonin; Vasculogenic mimicry

Mesh:

Substances:

Year:  2020        PMID: 32580038     DOI: 10.1016/j.ejphar.2020.173282

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  10 in total

1.  [Melatonin inhibits growth and metastasis of MDA-MB-231 breast cancer cells by activating autophagy].

Authors:  D Wu; Y Zhang; H Tang; J Yang; M Li; H Liu; Q Li
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-02-20

2.  Lupeol and Paclitaxel cooperate in hindering hypoxia induced vasculogenic mimicry via suppression of HIF-1α-EphA2-Laminin-5γ2 network in human oral cancer.

Authors:  Depanwita Saha; Debarpan Mitra; Neyaz Alam; Sagar Sen; Saunak Mitra Mustafi; Pradip K Majumder; Biswanath Majumder; Nabendu Murmu
Journal:  J Cell Commun Signal       Date:  2022-09-05       Impact factor: 5.908

Review 3.  The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment.

Authors:  Asieh Emami Nejad; Simin Najafgholian; Alireza Rostami; Alireza Sistani; Samaneh Shojaeifar; Mojgan Esparvarinha; Reza Nedaeinia; Shaghayegh Haghjooy Javanmard; Marjan Taherian; Mojtaba Ahmadlou; Rasoul Salehi; Bahman Sadeghi; Mostafa Manian
Journal:  Cancer Cell Int       Date:  2021-01-20       Impact factor: 5.722

4.  Thymoquinone inhibited vasculogenic capacity and promoted mesenchymal-epithelial transition of human breast cancer stem cells.

Authors:  Reza Rahbarghazi; Mohammad Nouri; Sanya Haiaty; Mohammad-Reza Rashidi; Maryam Akbarzadeh; Ahad Bazmany; Mostafa Mostafazadeh; Saba Nikanfar; Zohre Zibaei
Journal:  BMC Complement Med Ther       Date:  2021-03-04

5.  Cooperation Between Cancer and Fibroblasts in Vascular Mimicry and N2-Type Neutrophil Recruitment via Notch2-Jagged1 Interaction in Lung Cancer.

Authors:  Ying-Ming Tsai; Kuan-Li Wu; Yu-Wei Liu; Wei-An Chang; Yung-Chi Huang; Chao-Yuan Chang; Pei-Hsun Tsai; Szi-Hui Liao; Jen-Yu Hung; Ya-Ling Hsu
Journal:  Front Oncol       Date:  2021-08-17       Impact factor: 6.244

Review 6.  Melatonin and the Programming of Stem Cells.

Authors:  Rüdiger Hardeland
Journal:  Int J Mol Sci       Date:  2022-02-10       Impact factor: 5.923

Review 7.  Melatonin: highlighting its use as a potential treatment for SARS-CoV-2 infection.

Authors:  Russel J Reiter; Ramaswamy Sharma; Fedor Simko; Alberto Dominguez-Rodriguez; Jan Tesarik; Richard L Neel; Andrzej T Slominski; Konrad Kleszczynski; Verna M Martin-Gimenez; Walter Manucha; Daniel P Cardinali
Journal:  Cell Mol Life Sci       Date:  2022-02-20       Impact factor: 9.207

Review 8.  Use of Melatonin in Cancer Treatment: Where Are We?

Authors:  Leilei Wang; Chuan Wang; Wing Shan Choi
Journal:  Int J Mol Sci       Date:  2022-03-29       Impact factor: 5.923

9.  Identification of COX4I2 as a hypoxia-associated gene acting through FGF1 to promote EMT and angiogenesis in CRC.

Authors:  Jie-Pin Li; Yuan-Jie Liu; Shu-Hong Zeng; Hai-Jian Gao; Yu-Gen Chen; Xi Zou
Journal:  Cell Mol Biol Lett       Date:  2022-09-05       Impact factor: 8.702

Review 10.  Potential Therapeutic Effects of Melatonin Mediate via miRNAs in Cancer.

Authors:  Pirouz Pourmohammad; Nazila Fathi Maroufi; Mohsen Rashidi; Vahid Vahedian; Farhad Pouremamali; Yousef Faridvand; Mahsa Ghaffari-Novin; Alireza Isazadeh; Saba Hajazimian; Hamid Reza Nejabati; Mohammad Nouri
Journal:  Biochem Genet       Date:  2021-06-28       Impact factor: 1.890

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.